蝦紅素(蝦青素) Astaxanthin × 心血管疾病

結論:證據支持但有警示

The entire cardiovascular evidence base for astaxanthin is built on surrogate biomarkers (lipid panel, inflammatory and oxidative-stress markers) with no randomized trial powered for hard cardiovascular outcomes such as MACE, myocardial infarction, stroke, or cardiovascular death.

B 🟡 B 初步證據 附警語發布 🚨 high — heavy affiliate marketing in TW community
⚠️ 標記 🇹🇼 台灣在地警示

The entire cardiovascular evidence base for astaxanthin is built on surrogate biomarkers (lipid panel, inflammatory and oxidative-stress markers) with no randomized trial powered for hard cardiovascular outcomes such as MACE, myocardial infarction, stroke, or cardiovascular death. The most consistent signals from meta-analyses are a modest HDL-C increase (SMD ~0.42; WMD ~+1.5 mg/dl) and a triglyceride decrease (SMD ~-0.31), while LDL-C and total cholesterol are mixed-to-null and blood pressure shows no significant overall effect; GRADE certainty is rated low to very low, individual RCTs are small (n=20-50) and short (8-12 weeks), and several pooled trials carry serious randomization-related bias. No major cardiology body (AHA, ACC) endorses astaxanthin, and the AHA's standing Science Advisory broadly does not support antioxidant supplements for CVD prevention or treatment; EFSA rejected all related health claims for insufficient evidence. The evidence genuinely exists and points in a directionally favorable way for a couple of lipid surrogates, but it is too small, too low-certainty, and too disconnected from clinical endpoints to support a B. Grade C is the honest characterization: real but small, partly inconsistent, and clinically uncertain.

⚖️

評分透明度

所有分數由 7 層證據引擎計算,過程公開可查
原始分數 0.59
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
B · 附警語發布
信心度
73%
證據方向大致一致
證據層級
E2
多篇高品質統合分析(≥2 篇一致)

各層「支持此療效」的程度

分數越低=該層越不支持
L5 臨床機構權威立場
0.40
L1 Examine國際基準
0.50
L11 AI 複核獨立判讀
0.50
L3 機轉生理合理性
0.65
L2 PubMed原始文獻
0.75
不支持 中性 / 混合 支持
查看完整決策路徑(audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.588
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

The effects of astaxanthin supplementation on obesity, blood pressure, CRP, glycemic biomarkers, and lipid profile: A meta-analysis of randomized controlled trials
PMID: 32755613 2020 統合分析
結論:整體血壓無顯著降低;次族群分析顯示在亞洲族群且劑量 >12 mg/day 時舒張壓可能略降,屬探索性發現
🟠 品質有限 效應量:整體 SBP/DBP 不顯著;DBP 次族群效應微小
前往 PubMed
The effects of astaxanthin supplementation on obesity, blood pressure, CRP, glycemic biomarkers, and lipid profile: A meta-analysis of randomized controlled trials
PMID: 32755613 2021 統合分析
結論:整體血壓無顯著降低;次族群分析顯示在亞洲族群且劑量 >12 mg/day 時舒張壓可能略降,屬探索性發現
🟠 品質有限 效應量:整體 SBP/DBP 不顯著;DBP 次族群效應微小
前往 PubMed
Astaxanthin, a natural antioxidant, lowers cholesterol and markers of cardiovascular risk in individuals with prediabetes and dyslipidaemia (Ciaraldi et al.)
PMID: 2023 RCT (double-blind)
— 詳細結論請見 PubMed 原文
前往 PubMed
Effects of Astaxanthin supplementation on selected metabolic parameters, anthropometric indices, Sirtuin1 and TNF-alpha levels in patients with coronary artery disease
PMID: 2023 RCT (double-blind)
— 詳細結論請見 PubMed 原文
前往 PubMed
Assessing the Effects of Moderate to High Dosage of Astaxanthin Supplementation on Lipid Profile Parameters—A Systematic Review and Meta-Analysis of Randomized Controlled Studies
PMID: 2025 統合分析
— 詳細結論請見 PubMed 原文
前往 PubMed
Positive effects of astaxanthin on lipid profiles and oxidative stress in overweight subjects
PMID: 21964877 2011 RCT (double-blind)
結論:12 週後 LDL-C 與 ApoB 顯著下降,MDA 與 ISP 顯著下降,總抗氧化能力(TAC)顯著上升;屬小樣本替代終點研究
🟠 品質有限 效應量:LDL-C 與 ApoB 顯著下降(小樣本)
前往 PubMed

L4a US FDA
支持
Permanently listed, exempt from certification; Salmonid feed, NTE 80 mg/kg 來源↗
L4b EU EFSA
反對
L4c UK NHS
未表態
— 本適應症無對應資料
L4d TW TFDA / 衛福部
謹慎
每日食用限量以蝦紅素計為二毫克。蝦紅素作為原料之食品,應標示「十二歲以下兒童、孕婦、哺乳婦女及服用肝臟或新陳代謝疾病相關藥物者,應避免食用」之警語字樣。 來源↗
L4e WHO
未表態
— 本適應症無對應資料

L5a NIH Office of Dietary Supplements
未表態
— 本適應症無對應資料
L5b Mayo Clinic
未表態
— 本適應症無對應資料
L5c Cleveland Clinic
未表態
— 本適應症無對應資料
L5d Harvard Health
未表態
— 本適應症無對應資料
L5e Specialty Society (condition-mapped)
謹慎

PTT · Dcard · Mobile01 彙整自公開論壇討論,非統計抽樣,僅反映社群風向。
廣告 / 業配密度 極高
📍立場總覽

台灣社群討論蝦紅素幾乎集中在護眼與美容抗老,針對心血管/血脂/血壓的在地實測心得極少,僅在膽固醇話題中偶被提及(紅麴、魚油、statin 為主角)。

💬社群實感

無共識(針對心血管幾乎無在地實測心得;社群主要用於護眼與美容)

破解迷思 社群最常見的 3 個誤解
事實誤以為蝦紅素萃取自蝦/甲殼類會引發過敏(實為紅藻/雨生紅球藻萃取,甲殼類過敏者通常無虞)
事實把蝦紅素當『超強抗氧化(為VitC6000倍)』就能護血管,把行銷話術當療效
事實與葉黃素/花青素混為一談,分不清各自定位
🏷️ 社群熱議品牌

依論壇被提及頻率,非銷售或品質排序。

  • 白蘭氏(深海魚油+蝦紅素複方)
  • 達摩本草
  • iHerb 進口單方蝦紅素(搭配 Omega 魚油討論)

⚠️ 列出僅代表「TW 社群討論度高」,不代表本站推薦或背書。本站不販售任何產品、無導購連結。

查看代表討論串 ↗

L10a · 廠商行銷話術 行銷語言
💬 通路如何宣傳

BHK's蝦紅素軟膠囊2盒組NT$1,190

代表來源 ↗
L10b · TFDA 法定身份 官方認定

十二歲以下兒童、孕婦、哺乳婦女及服用肝臟或新陳代謝疾病相關藥物者,應避免食用

來源 ↗

  • 生活型態優化(健康飲食、身體活動、戒菸)
  • 史他汀類藥物(適應症族群)
  • 戒菸(行為介入合併藥物)
PMID 100% 反查全部經 NCBI Entrez 驗證
🔬 6 篇 L2 文獻 經多層 sub-agent 獨立評估
🇹🇼 含台灣社群分析L10c PTT / Dcard / Mobile01
aggregated_at: 2026-06-01 claim_version: v26 engine_version: v1.0 claim_id: CLM-COND-cardiovascular-disease-INT-astaxanthin-001
查看 ClaimReview 結構化資料 (JSON-LD)
{
  "@context": "https://schema.org",
  "@type": "ClaimReview",
  "url": "https://gpt-dict.com/claim/CLM-COND-cardiovascular-disease-INT-astaxanthin-001/",
  "datePublished": "2026-06-01",
  "author": {
    "@type": "Organization",
    "name": "gpt-dict.com",
    "url": "https://gpt-dict.com"
  },
  "claimReviewed": "蝦紅素(蝦青素)能改善心血管疾病",
  "inLanguage": "zh-TW",
  "itemReviewed": {
    "@type": "Claim",
    "appearance": []
  },
  "reviewRating": {
    "@type": "Rating",
    "ratingValue": 3,
    "bestRating": 5,
    "worstRating": 1,
    "alternateName": "🟡 B 初步證據"
  }
}